Replies to post #202474 on Biotech Values

[mcbio]

In other words, I don't think these switches are going to be a *feature* for CAR-T therapy. My bet is they'll turn out to be like training wheels... useful as a commodity tech while companies figure out the CAR-T paradigm, but obsolete long-term.

If your concerns are proven correct, guess the big key here is definition of "long-term." As a BLCM and CLLS long, I would have to hope there is at least enough of a window in the interim where other players (JUNO?) would be convinced of the utility of a safety switch or at least the market would better appreciate the concept. ; )

I think they have meaningful long-term applicability in other areas, so I'm purposefully limiting this viewpoint to CAR-T specifically.

Would be curious to hear what other areas you're referring to here.